Pfizer general counsel will no longer oversee its compliance programme under the terms of the $2.3bn (£1.4bn) settlement resolving allegations of illegal marketing of painkiller Bextra and several other drugs, writes Corporate Counsel.
Instead, the chief compliance officer at the world’s largest drug maker will report directly to the chief executive. The move is required by Pfizer’s corporate integrity agreement with the office of the inspector general of the US Department of Health and Human Services (HHS), part of the company’s civil and criminal settlement with the Department of Justice.
